The $49 million in tokenization and licensing agreements secured by Datavault AI (DVLT) in Q4 2025 are projected to have a substantial positive impact on the company's FY2026 revenue. The company has explicitly stated that these agreements influence both FY2025 and FY2026 revenue.1
Impact on FY2026 Revenue Projections
Datavault AI has significantly revised its revenue outlook for FY2026 following these agreements.
- Updated Guidance: The company now expects at least $200 million in revenue for FY2026.1
- Previous Guidance: This represents a substantial increase from earlier guidance, which had targeted FY2026 revenue between $40 million and $50 million as of April 2025.2
This upward revision underscores the material contribution expected from the Q4 2025 agreements. For context, Datavault AI anticipates at least $30 million in revenue for FY2025, up from $2.7 million in FY2024, indicating a rapid growth trajectory.1
Nature of the Agreements
The $49 million in agreements include key strategic partnerships that are designed to drive long-term revenue streams:
- NYIAX Partnership: A multi-year commercial and intellectual property (IP) licensing agreement with NYIAX, integrating Datavault AI's patented Information Data Exchange® (IDE) and Data Vault® platform with NYIAX's blockchain exchange technology. This aims to enable efficient listing, pricing, and trading of data and digital assets.1
- Scilex Exclusive License: A worldwide exclusive license granted to Scilex for Datavault AI's AI-driven technology, specifically for use within the biotech and biopharma industry. This agreement is intended to facilitate secure tokenization, trading, and monetization of biotech assets, including genomic and DNA data.1
These agreements suggest that the $49 million likely represents a combination of upfront licensing fees and potential recurring revenue components, which will be recognized over the life of the multi-year contracts, contributing significantly to the accelerated FY2026 revenue forecast.
